Re-routing Metabolism by the Mitochondrial Pyruvate Carrier Inhibitor MSDC-0160 Attenuates Neurodegeneration in a Rat Model of Parkinson’s Disease
- 27 July 2022
- journal article
- research article
- Published by Springer Nature in Molecular Neurobiology
- Vol. 59 (10) , 6170-6182
Abstract
A growing body of evidence supports the idea that mitochondrial dysfunction might represent a key feature of Parkinson’s disease (PD). Central regulators of energy production, mitochondria, are also involved in several other essential functions such as cell death pathways and neuroinflammation which make them a potential therapeutic target for PD management. Interestingly, recent studies related to PD have reported a neuroprotective effect of targeting mitochondrial pyruvate carrier (MPC) by the insulin sensitizer MSDC-0160. As the sole point of entry of pyruvate into the mitochondrial matrix, MPC plays a crucial role in energetic metabolism which is impacted in PD. This study therefore aimed at providing insights into the mechanisms underlying the neuroprotective effect of MSDC-0160. We investigated behavioral, cellular, and metabolic impact of chronic MSDC-0160 treatment in unilateral 6-OHDA PD rats. We evaluated mitochondrially related processes through the expression of pivotal mitochondrial enzymes in dorsal striatal biopsies and the level of metabolites in serum samples using nuclear magnetic resonance spectroscopy (NMR)–based metabolomics. MSDC-0160 treatment in unilateral 6-OHDA rats improved motor behavior, decreased dopaminergic denervation, and reduced mTOR activity and neuroinflammation. Concomitantly, MSDC-0160 administration strongly modified energy metabolism as revealed by increased ketogenesis, beta oxidation, and glutamate oxidation to satisfy energy needs and maintain energy homeostasis. MSDC-0160 exerts its neuroprotective effect through reorganization of multiple pathways connected to energy metabolism.Keywords
All Related Versions
Funding Information
- Agence Nationale de la Recherche (ANR-16-CE16-0002, ANR-11-INBS-0006)
- Fondation de France (00086205)
- Association France Parkinson
This publication has 83 references indexed in Scilit:
- Autophagic Impairment Contributes to Systemic Inflammation-Induced Dopaminergic Neuron Loss in the MidbrainPLOS ONE, 2013
- Thiazolidinediones are acute, specific inhibitors of the mitochondrial pyruvate carrierProceedings of the National Academy of Sciences, 2013
- Effect of 6-hydroxydopamine (6-OHDA) on proliferation of glial cells in the rat cortex and striatum: evidence for de-differentiation of resident astrocytesCell and tissue research, 2010
- An animal model of PDH deficiency using AAV8-siRNA vector-mediated knockdown of pyruvate dehydrogenase E1αMolecular Genetics and Metabolism, 2010
- Neuroinflammation in Parkinson's disease: Its role in neuronal death and implications for therapeutic interventionNeurobiology of Disease, 2010
- Metabolic profiling of Parkinson's disease: evidence of biomarker from gene expression analysis and rapid neural network detectionJournal of Biomedical Science, 2009
- Involvement of Nitric Oxide in Nigrostriatal Dopaminergic System DegenerationAnnals of the New York Academy of Sciences, 2009
- Multinuclear Magnetic Resonance Spectroscopy for in Vivo Assessment of Mitochondrial Dysfunction in Parkinson's DiseaseAnnals of the New York Academy of Sciences, 2008
- The brain-specific carnitine palmitoyltransferase-1c regulates energy homeostasisProceedings of the National Academy of Sciences, 2006
- Energy Metabolism in Rat Brain: Inhibition of Pyruvate Decarboxylation by 3‐Hydroxybutyrate in Neonatal MitochondriaJournal of Neurochemistry, 1981